Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL ACT in Metastatic Ovarian Cancer
NCT03412526Phase 2Unknown
- Sponsor
- Sheba Medical Center
- Start
- Jan 2018
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in ovarian cancer, sponsored by Sheba Medical Center. Status: unknown.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03412526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412526.